(Q42673085)

4 November 2017

title

In vitro effects of folate derivatives on valproate-induced neural tube defects in mouse and rat embryos (English)

1 reference

4 November 2017

1 reference

D. K. Hansen

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20732274

21 June 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20732274

21 June 2024

publication date

1 November 1993

1 reference

full work available at URL

4 November 2017

https://api.elsevier.com/content/article/PII:088723339390075G?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/0887-2333(93)90075-G

https://api.elsevier.com/content/article/PII:088723339390075G?httpAccept=text/plain

21 June 2024

1 reference

https://api.crossref.org/works/10.1016/0887-2333(93)90075-G

21 June 2024

1 reference

4 November 2017

volume

7

1 reference

4 November 2017

issue

6

1 reference

4 November 2017

page(s)

735-742

1 reference

Verification of the fetal valproate syndrome phenotype

4 November 2017

cites work

2

1 reference

https://api.crossref.org/works/10.1016/0887-2333(93)90075-G

Valproic acid and spina bifida

21 June 2024

3

1 reference

https://api.crossref.org/works/10.1016/0887-2333(93)90075-G

Quantitation of rat embryonic development in vitro: A morphological scoring system

21 June 2024

4

1 reference

https://api.crossref.org/works/10.1016/0887-2333(93)90075-G

Effect of chronic valproate treatment on folate-dependent methyl biosynthesis in the rat

21 June 2024

5

1 reference

https://api.crossref.org/works/10.1016/0887-2333(93)90075-G

21 June 2024

Fetal valproate syndrome

6

1 reference

https://api.crossref.org/works/10.1016/0887-2333(93)90075-G

Valproic acid teratogenicity in whole embryo culture is not prevented by zinc supplementation

21 June 2024

8

1 reference

https://api.crossref.org/works/10.1016/0887-2333(93)90075-G

Short-chain carboxylic acids, a new class of teratogens: studies of potential biochemical mechanisms

21 June 2024

9

1 reference

https://api.crossref.org/works/10.1016/0887-2333(93)90075-G

The fetal valproate syndrome

21 June 2024

11

1 reference

https://api.crossref.org/works/10.1016/0887-2333(93)90075-G

Effect of supplementation with folinic acid, vitamin B6, and vitamin B12 on valproic acid-induced teratogenesis in mice

21 June 2024

13

1 reference

https://api.crossref.org/works/10.1016/0887-2333(93)90075-G

Teratogenic effects of dosage levels and time of administration of carbamazepine, sodium valproate, and diphenylhydantoin on craniofacial development in the CD-1 mouse fetus

21 June 2024

14

1 reference

https://api.crossref.org/works/10.1016/0887-2333(93)90075-G

Variation in development of rat embryos at the presomite period

21 June 2024

15

1 reference

https://api.crossref.org/works/10.1016/0887-2333(93)90075-G

The in vitro embryotoxicity of 5-fluorouracil in rat embryos.

21 June 2024

16

1 reference

https://api.crossref.org/works/10.1016/0887-2333(93)90075-G

Lack of attenuation of valproic acid-induced effects by folinic acid in rat embryos in vitro

21 June 2024

18

1 reference

https://api.crossref.org/works/10.1016/0887-2333(93)90075-G

Effects of valproic acid, some of its metabolites and analogues on prenatal development of rats in vitro and comparison with effects in vivo.

21 June 2024

21

1 reference

https://api.crossref.org/works/10.1016/0887-2333(93)90075-G

A simple, rapid, and sensitive DNA assay procedure

21 June 2024

22

1 reference

https://api.crossref.org/works/10.1016/0887-2333(93)90075-G

Pharmacokinetic aspects of drug effects in vitro: effects of serum protein binding on concentration and teratogenicity of valproic acid and 2-en-valproic acid in whole embryos in culture

21 June 2024

23

1 reference

https://api.crossref.org/works/10.1016/0887-2333(93)90075-G

In-utero exposure to valproate and neural tube defects.

21 June 2024

24

1 reference

https://api.crossref.org/works/10.1016/0887-2333(93)90075-G

Protein measurement with the Folin phenol reagent

21 June 2024

25

1 reference

https://api.crossref.org/works/10.1016/0887-2333(93)90075-G

Predicting the human teratogenic potential of the anticonvulsant, valproic acid, from a non-human primate model

21 June 2024

26

1 reference

https://api.crossref.org/works/10.1016/0887-2333(93)90075-G

Growth of 9.5-day rat embryos in folic-acid-deficient serum

21 June 2024

27

1 reference

https://api.crossref.org/works/10.1016/0887-2333(93)90075-G

Multivitamin/folic acid supplementation in early pregnancy reduces the prevalence of neural tube defects

21 June 2024

28

1 reference

https://api.crossref.org/works/10.1016/0887-2333(93)90075-G

Recommendations for the use of folic acid to reduce the number of cases of spina bifida and other neural tube defects

21 June 2024

29

1 reference

https://api.crossref.org/works/10.1016/0887-2333(93)90075-G

Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. MRC Vitamin Study Research Group

21 June 2024

30

1 reference

https://api.crossref.org/works/10.1016/0887-2333(93)90075-G

Reproduction in the rat on purified diets containing succinylsulfathiazole

21 June 2024

31

1 reference

https://api.crossref.org/works/10.1016/0887-2333(93)90075-G

Whole-embryo culture and the study of mammalian embryos during organogenesis

21 June 2024

32

1 reference

https://api.crossref.org/works/10.1016/0887-2333(93)90075-G

Teratogenesis of calcium valproate in rats

21 June 2024

33

1 reference

https://api.crossref.org/works/10.1016/0887-2333(93)90075-G

Teratogenic effects of valproate in the CD-1 mouse fetus

21 June 2024

34

1 reference

https://api.crossref.org/works/10.1016/0887-2333(93)90075-G

Teratogenesis of calcium valproate in rabbits

21 June 2024

35

1 reference

https://api.crossref.org/works/10.1016/0887-2333(93)90075-G

Valproate hydroxylation by human fetal tissues and embryotoxicity of metabolites

21 June 2024

36

1 reference

https://api.crossref.org/works/10.1016/0887-2333(93)90075-G

Maternal valproic acid and congenital neural tube defects

21 June 2024

37

1 reference

https://api.crossref.org/works/10.1016/0887-2333(93)90075-G

Intestinal absorption of folates

21 June 2024

38

1 reference

https://api.crossref.org/works/10.1016/0887-2333(93)90075-G

Interactions between folates and carbamazepine or valproate in the rat.

21 June 2024

39

1 reference

https://api.crossref.org/works/10.1016/0887-2333(93)90075-G

Apparent prevention of neural tube defects by periconceptional vitamin supplementation

21 June 2024

40

1 reference

https://api.crossref.org/works/10.1016/0887-2333(93)90075-G

Possible valproate teratogenicity

21 June 2024

41

1 reference

https://api.crossref.org/works/10.1016/0887-2333(93)90075-G

Valproic acid-induced neural tube defects: reduction by folinic acid in the mouse

21 June 2024

42

1 reference

https://api.crossref.org/works/10.1016/0887-2333(93)90075-G

Diurnal variation of folate concentrations in mouse embryo and plasma: The protective effect of folinic acid on valproic-acid-induced teratogenicity is time dependent

21 June 2024

43

1 reference

https://api.crossref.org/works/10.1016/0887-2333(93)90075-G

Fetal valproate syndrome: is there a recognisable phenotype?

21 June 2024

44

1 reference

https://api.crossref.org/works/10.1016/0887-2333(93)90075-G

21 June 2024

Identifiers

1 reference

4 November 2017

1 reference